A once-weekly GLP-1 agonist built as an antibody-fragment fusion.
Also known as: Trulicity
Part of the Metabolic & GLP-1 peptides cluster
Overview
Dulaglutide is a GLP-1 receptor agonist in which two modified GLP-1 peptide chains are fused to a human immunoglobulin (IgG4) Fc fragment. The large fusion greatly extends half-life, allowing once-weekly dosing. It is an approved prescription drug, and this page is educational only.
Source & context
Biological / chemical source: Recombinant GLP-1 analog fused to a human IgG4 Fc fragment
Primary research or clinical context: Prescription medicine approved in Canada, the US and EU
Fusion-protein design
Rather than acylation, dulaglutide links a DPP-4-resistant GLP-1 analog to an antibody Fc region. The Fc scaffold raises molecular size and recycles through the neonatal Fc receptor, extending circulation to roughly a week. It is not a single small peptide, so no compact residue count describes the whole molecule.
Approval and status
Marketed as Trulicity, dulaglutide is an approved prescription medicine in Canada, the US and EU. As a regulated therapeutic it is used only under a prescriber's direction. This summary covers the molecular engineering behind the peptide for educational purposes and makes no therapeutic claims.
FAQ about Dulaglutide
What is Dulaglutide?+
Dulaglutide is a GLP-1 receptor agonist in which two modified GLP-1 peptide chains are fused to a human immunoglobulin (IgG4) Fc fragment. The large fusion greatly extends half-life, allowing once-weekly dosing. It is an approved prescription drug, and this page is educational only.
Is Dulaglutide an approved medicine?+
Dulaglutide: Prescription medicine approved in Canada, the US and EU. Always follow licensed medical guidance for approved products.
What is the typical length of Dulaglutide?+
Dulaglutide is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.